Advanced in Lung Metastases

Shunji Takahashi

Tokyo, JP 
Advanced in Lung Metastases
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Shunji Takahashi practices in Tokyo, Japan. Takahashi is rated as an Advanced expert by MediFind in the treatment of Lung Metastases. Their top areas of expertise are Anaplastic Thyroid Cancer, Breast Cancer, Adult Soft Tissue Sarcoma, Endoscopy, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 510 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Lung Metastases.

Locations

Tokyo, Japan
Other Locations
Wako, 3510198, Japan
Ariake, 1358550, Japan
Saitama, 3510198, Japan
1358550, Japan
Sakuracho, 3388570, Japan
Koto, Japan
Yokohama, Japan
Yayoi, 1138657, Japan
Kobe, Japan
Asahi, 5458585, Japan
Hirosawa, 3510198, Japan
Sennan, 5900494, Japan
Kyoto, Japan
Asahimachi, 5458585, Japan
Osaka, Japan
Tohoku, 9808577, Japan
Niigata Prefecture Head And Neck Malignant Tumour Registration Committee, Niigata, Japan
Sendai, Japan
Sapporo, 0608604, Japan
Hongo, 1138656, Japan
Nagasaki, Japan
Toshima, 1708455, Japan
Chiba, 2608670, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: July 06, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

510 Total Publications

Structural insights into a bacterial terpene cyclase fused with haloacid Dehalogenase-like phosphatase.
Structural insights into a bacterial terpene cyclase fused with haloacid Dehalogenase-like phosphatase.
Journal: Chemical science
Published: June 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Takahashi's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile